These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 9443356)

  • 1. Schizophrenia, psychosis, and the basal ganglia.
    Busatto GF; Kerwin RW
    Psychiatr Clin North Am; 1997 Dec; 20(4):897-910. PubMed ID: 9443356
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dopaminergic dysbalance in distinct basal ganglia neurocircuits: implications for the pathophysiology of Parkinson's disease, schizophrenia and attention deficit hyperactivity disorder.
    Mehler-Wex C; Riederer P; Gerlach M
    Neurotox Res; 2006 Dec; 10(3-4):167-79. PubMed ID: 17197367
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Forebrain dopamine systems--can they help us to understand psychosis?
    Grace A
    Eur Psychiatry; 2003 Dec; 18 Suppl 2():27s-31s. PubMed ID: 23570193
    [No Abstract]   [Full Text] [Related]  

  • 4. Optimal extent of dopamine D2 receptor occupancy by antipsychotics for treatment of dopamine supersensitivity psychosis and late-onset psychosis.
    Iyo M; Tadokoro S; Kanahara N; Hashimoto T; Niitsu T; Watanabe H; Hashimoto K
    J Clin Psychopharmacol; 2013 Jun; 33(3):398-404. PubMed ID: 23609386
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Basal ganglia volumetric changes in psychotic spectrum disorders.
    Liu C; Cao B; Yu R; Sim K
    J Affect Disord; 2019 Aug; 255():150-157. PubMed ID: 31153051
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 5-HT1A receptor-dependent control of nigrostriatal dopamine neurotransmission in the pharmacotherapy of Parkinson's disease and schizophrenia.
    Haleem DJ
    Behav Pharmacol; 2015 Feb; 26(1-2):45-58. PubMed ID: 25503261
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emerging therapeutic targets for schizophrenia: a framework for novel treatment strategies for psychosis.
    Sonnenschein SF; Grace A
    Expert Opin Ther Targets; 2021 Jan; 25(1):15-26. PubMed ID: 33170748
    [No Abstract]   [Full Text] [Related]  

  • 8. Dysfunctions in multiple interrelated systems as the neurobiological bases of schizophrenic symptom clusters.
    O'Donnell P; Grace AA
    Schizophr Bull; 1998; 24(2):267-83. PubMed ID: 9613625
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Different effects of typical and atypical antipsychotics on grey matter in first episode psychosis: the AESOP study.
    Dazzan P; Morgan KD; Orr K; Hutchinson G; Chitnis X; Suckling J; Fearon P; McGuire PK; Mallett RM; Jones PB; Leff J; Murray RM
    Neuropsychopharmacology; 2005 Apr; 30(4):765-74. PubMed ID: 15702141
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neural basis of psychosis-related behaviour in the infection model of schizophrenia.
    Meyer U; Feldon J
    Behav Brain Res; 2009 Dec; 204(2):322-34. PubMed ID: 19154759
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pre-pulse inhibition and striatal dopamine in subjects at an ultra-high risk for psychosis.
    De Koning MB; Bloemen OJ; Van Duin ED; Booij J; Abel KM; De Haan L; Linszen DH; Van Amelsvoort TA
    J Psychopharmacol; 2014 Jun; 28(6):553-60. PubMed ID: 24526133
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mesolimbic dopamine D3 receptors and use of antipsychotics in patients with schizophrenia. A postmortem study.
    Gurevich EV; Bordelon Y; Shapiro RM; Arnold SE; Gur RE; Joyce JN
    Arch Gen Psychiatry; 1997 Mar; 54(3):225-32. PubMed ID: 9075463
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cortical stress regulation is disrupted in schizophrenia but not in clinical high risk for psychosis.
    Schifani C; Tseng HH; Kenk M; Tagore A; Kiang M; Wilson AA; Houle S; Rusjan PM; Mizrahi R
    Brain; 2018 Jul; 141(7):2213-2224. PubMed ID: 29860329
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antipsychotic-Induced Dopamine Supersensitivity Psychosis: Pharmacology, Criteria, and Therapy.
    Chouinard G; Samaha AN; Chouinard VA; Peretti CS; Kanahara N; Takase M; Iyo M
    Psychother Psychosom; 2017; 86(4):189-219. PubMed ID: 28647739
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dopamine partial agonist action of (-)OSU6162 is consistent with dopamine hyperactivity in psychosis.
    Seeman P; Guan HC
    Eur J Pharmacol; 2007 Feb; 557(2-3):151-3. PubMed ID: 17157291
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tardive dyskinesia: pathophysiology and animal models.
    Casey DE
    J Clin Psychiatry; 2000; 61 Suppl 4():5-9. PubMed ID: 10739324
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PET examination of central D2 dopamine receptor occupancy in relation to extrapyramidal syndromes in patients being treated with neuroleptic drugs.
    Farde L; Nordström AL
    Psychopharmacol Ser; 1993; 10():94-100. PubMed ID: 8103229
    [No Abstract]   [Full Text] [Related]  

  • 18. Differential effects of aripiprazole on D(2), 5-HT(2), and 5-HT(1A) receptor occupancy in patients with schizophrenia: a triple tracer PET study.
    Mamo D; Graff A; Mizrahi R; Shammi CM; Romeyer F; Kapur S
    Am J Psychiatry; 2007 Sep; 164(9):1411-7. PubMed ID: 17728427
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Schizophrenia: more dopamine, more D2 receptors.
    Seeman P; Kapur S
    Proc Natl Acad Sci U S A; 2000 Jul; 97(14):7673-5. PubMed ID: 10884398
    [No Abstract]   [Full Text] [Related]  

  • 20. Motor abnormalities and basal ganglia in schizophrenia: evidence from structural magnetic resonance imaging.
    Hirjak D; Wolf RC; Wilder-Smith EP; Kubera KM; Thomann PA
    Brain Topogr; 2015 Jan; 28(1):135-52. PubMed ID: 24878894
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.